The company reported disappointing fourth-quarter results.
News & Analysis: Fluidigm
The company is now cleared to sell its saliva-based COVID-19 test in Europe.
Is this cell analysis hardware company's stock a pricey lottery ticket, or an undervalued diamond in the rough?
The labs are each processing three-thousand tests per day.
Even top diagnostic test producers got hit hard in late August.
The coronavirus testing market is suddenly a lot more crowded.
The Nasdaq Composite failed to hit a record for the first time in a week.
The FDA authorized the biological research equipment maker's new coronavirus test for emergency use.
The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.
Investors appear to be banking on the company winning FDA emergency use authorization for its Biomark system in COVID-19 testing.